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Inhypertensivesubjects,angiotensinIIandendothelinparticipateinamannerinvolvingcloselyinterwovenpathwaysinincreasing
blood pressure (BP) and inducing end organ damage. The primary objective of this study was to determine the eﬀect of
TRC120038, a novel dual AT1/ETA receptor blocker on BP, in obese Zucker spontaneously hypertensive fatty rats (ob-ZSF1), an
animal model of moderate hypertension, diabetes with progressive renal and cardiac dysfunction. Ob-ZSF1 rats loaded with 0.5%
salt were treated with TRC120038 (11.8mg/kg bid.) or candesartan cilexetil (0.3mg/kg od.) or vehicle control. Blood pressure (by
radio-telemetry) and renal functional markers were monitored throughout the study. Cardiac function was assessed terminally
by pressure volume catheter. Markers for renal dysfunction were measured and changes were evaluated histopathologically.
TRC120038 showed greater fall in both systolic and diastolic BP in comparison to candesartan at its maximum antihypertensive
dose. TRC120038 also reduced the severity of renal dysfunction and preserved cardiac function in ob-ZSF1 rat.
1.Introduction
Inspite of multihypertensive drug treatment, signiﬁcant
proportion of poorly controlled hypertensives exist [1–3].
Greaterincidencesofstroke,heartfailure,andendstagerenal
disease are reported in these patients [4, 5]; rigorous blood
pressure (BP) lowering treatment targets are recommended
for these patient population [6, 7].
Hypertensive patients have upregulated endothelin and
renin angiotensin system (RAS). This has been clearly
shown by elevated plasma levels of endothelin-1 (ET-1)
[8] and plasma renin activity [9] in such subjects. More
recently, endothelin receptor blockers have shown to be
eﬀective in resistant hypertensives [10]. It is now well
established that increased ET-1 activity is one of the con-
tributors for increased incidence of hypertension in diabetics
with insulin resistance [11–13]. Similarly, association of
increased body mass index with enhanced-ETA-receptor-
dependent vasoconstrictor activity in hypertensive subjects
has been demonstrated [13–15]. A substantial part of the
poor responders to current antihypertensive therapy is
characterized by salt sensitivity and increased-ETA-receptor-
dependent vasoconstrictor tone [16, 17]. Such evidence
suggests that abnormality in the endothelin system (in
addition to RAS) plays a role in the pathophysiology of
poorly controlled/diﬃcult to treat (obesity- and diabetic-
related) hypertension and that targeting endothelin system
in addition to the RAS is a useful treatment for hypertension
in these patients.
Diabetic nephropathy, characterized by progressive rise
in BP, persistent albuminuria, and declining glomerular
ﬁltration rate, remains the leading cause of end stage
renal disease requiring renal replacement therapy. Clinical
evidence suggests that there is a large unmet need to develop
strategies for prevention of diabetic nephropathy and its
progression to end stage renal disease [18, 19].
Role of RAS in development of glomerular hypertension
and nephropathy is well established [20, 21]. Targeting RAS2 International Journal of Hypertension
through angiotensin receptor blockade is now a strategy
of choice to treat hypertension. This strategy has also
shown some promises in diabetic nephropathy. In addition,
ET-1 stimulates hypertrophy, proliferation, and extracellular
matrix accumulation in the kidney [22–24], which are
prevented by ETA receptors blockers [25, 26]. Similarly,
ETA receptor blockade has shown antiproteinuric eﬀects in
proteinuric chronic kidney disease patients [27].
Emerging experimental evidence from various studies
suggests that angiotensin II (Ang II) and endothelin par-
ticipate in a manner involving closely interwoven pathways
(crosstalk) in increasing BP and inducing end organ damage
[28–35]. The pharmacological beneﬁts of dual Ang II and
ET-1 blockade have been demonstrated in form of their anti-
hypertensiveandanti-proteinuric eﬀectsbothinrodentsand
humans [26, 36–39]. Hence, concomitant blockade of both
angiotensin and endothelin endocrine/paracrine pathways
may lead not only to enhanced BP reductions but also
retard end organ damage directly or indirectly. Molecules
with dual activity (dual receptor blockers) are like ﬁxed-
dose combination of two drugs which generally has the
limitation of inability for physicians to titrate the individual
dose of the combination for diﬀerential individual activity.
At the same time, adopting dual receptor blockers strategy
oﬀers unique advantages especially when both the actives
are contributing to overall similar therapeutic eﬀect. Better
patient compliance and lower production cost further add
utility of such approach in appropriate scenarios.
T h e s es t u d i e st h u sp r o v i d e dar a t i o n a l ef o rat h e r a p e u t i c
strategy to develop compounds with dual receptor blocker
action against AT1 and ETA receptors. Torrent’s discovery
program identiﬁed TRC120038, a novel dual AT1/ETA
receptor blocker. Candesartan cilexetil (candesartan), a
potent, long-acting, unsurmountable AT1 receptor blocker
used in clinic, with once-a-day dosing was selected to
be studied as the comparator to TRC120038. This study
was thus performed to compare the therapeutic potential
of TRC120038 and candesartan in reducing BP and end
organ damage (diabetic nephropathy and cardiomyopathy)
in obese Zucker spontaneously hypertensive fatty rats (ob-
ZSF1), an animal model with a severe form of diabetes
associated with clinically relevant comorbidities eventually
leading to progressive renal and cardiac dysfunction [40].
2. Methods
2.1. Test Compounds. The chemical name of TRC120038
is N-(4,5-dimethyl-1,2-oxazol-3-yl)-3-[4-{[4,6-dimethyl-3-
(thiophen-2-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl]methyl}-2-
(ethoxymethyl)phenyl]-5-methylthiophene-2-sulfona-mide,
and its chemical structure is presented in Figure 1.P a t e n t
was ﬁled and published under PCT (WO 2007/100295 A1).
This compound was synthesized by Torrent Pharmaceu-
ticals Ltd. TRC120038 and candesartan were formulated as
suspensions in 3% w/v hydroxyl propyl cellulose in water.
TRC120038, a novel dual AT1/ETA receptor blocker has an in
vitro EC50 of 3nM and 158nM for hAT1 and hETA receptor
blockade, respectively, along with reasonable selectivity
(>50x) against hAT2 and hETB receptors. TRC120038 has no
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Figure 1: Chemical structure of TRC120038.
signiﬁcant binding to any other receptors nor does it alter
the activity of any enzymes out of a wide battery of receptors
and enzymes tested on the PanLabs battery of assays.
2.2. Animals. Male ob-ZSF1 rats (Charles River Laborato-
ries, USA) were used in the study. All animals were main-
tained in the Pre-clinical and Safety Evaluation Department,
Torrent Research Centre, housed in individually ventilated
cages (IVC) system, maintained on a 12-hour light-dark
cycle, and had access to Purina 5008 rat chow and water
ad libitum. The IVCs were maintained under controlled
environment temperature (22±3◦C), relative humidity (30–
70%),andairexchangerate(40–50airchangesperhour).All
animal experiments were conducted in accordance with the
CPCSEA guidelines, and the studies were approved by the
Institutional Animal Ethics Committee.
2.3. Hemodynamic Measurements. Rats (180–250gm b.wt;
6–8 weeks of age) were implanted with radio-telemetry
transmitters (TA11PA-C40, Data Sciences, St. Paul, Minn,
USA) under 1.5% isoﬂurane anesthesia, and the abdominal
aorta was cannulated to place the tip of the gel-ﬁlled
transmitter catheter, caudal to the renal arteries for arterial
BP recording. BP data were collected with a computer-
driven data acquisition system (Dataquest A.R.T. 3.01,
Data Sciences); the acquisition software was appropriately
conﬁgured to record parameters for 10 seconds every 10
minutes, continuously for 21 hours. The mean of 0–19-hour
dataofBPrecordingofeachdaywascalculatedastheaverage
BP for the day. The BP of the rats was recorded once weekly
for 21 hours from 10 weeks of age till study termination at
around 41 weeks of age.
Rats at around 10 weeks of age were given 0.25%
sodium chloride (salt) dissolved in drinking water for a
week and then salt load increased to 0.5% (85.5mmol/L)
for the rest of the study, to accelerate the vasculopathy and
cardiomyopathy.International Journal of Hypertension 3
2.4. Antihypertensive Activity of TRC120038 and Candesartan
Dose Response. To establish the optimal treatment dose of
TRC120038 and candesartan for the chronic eﬃcacy study,
rats at around 12 weeks of age were randomized into six
treatment groups (n = 6 in each group), with matching
baseline mean blood pressure (MBP). On the ﬁrst day of
treatment, all rats in the six treatment groups were adminis-
tered vehicle (1mL/kg) by oral route; on the subsequent two
days, three treatment groups were administered TRC120038
(1.26, 11.8, 45.5mg/kg p.o., bid.) and the other three groups
received candesartan (0.03, 0.3 and 1mg/kg p.o., od.) in the
morning and vehicle 12 hours later in the evening. These
doses of TRC120038 and candesartan were derived from
eﬃcacy studies done earlier in our laboratory.
2.5. Repeat Dose Eﬃcacy Study with
TRC120038 and Candesartan
2.5.1. Drug Treatment. At the age of around 15 weeks, the
rats were randomly distributed into three treatment groups;
(n = 8–11 per group) on the basis of baseline MBP. Group1:
control group was administered vehicle (1mL/kg p.o., bid.);
group 2: TRC120038 group was administered 11.8mg/kg,
p.o., bid. and group 3: candesartan group was administered
0.3mg/kg, p.o., od. until study termination at around 41
weeks of age (25 weeks of treatment).
2.5.2. Estimation of Various Urine Biochemical Parameters.
The urine albumin, creatinine, and total protein were mon-
itored, before treatment initiation (treatment month 0, i.e.,
15 week of age) and were repeated monthly thereafter. Urine
samples were collected every 2 hours and stored at 2–4◦C
beforepooling 24-hoursamples.Totalproteinandcreatinine
were estimated using fully automated clinical chemistry
analyzer Olympus AU400 (Olympus Corporation, Japan).
Urinary albumin estimation was performed in accordance
with in-house method developed for estimating albumin
content in urine sample by HPLC.
2.5.3. Measurement of Left Ventricular (Cardiac) Performance.
Terminal measurement of left ventricular (LV) function
was performed using Millar Pressure Volume (PV) System
(Millar Instruments, Houston, Tex, USA). A microtip PV
catheter (SPR-838) was inserted into the right carotid
artery and advanced into the LV. Polyethylene catheter was
inserted into the left jugular for ﬂuid administration. After
stabilization for 10–20 minutes, LV-PV signals were recorded
continuously at a sampling rate of 1000/second using an
MPVS-300 conductance system (Millar Instruments) cou-
pled to a PowerLab 8/30 (ADInstruments, Australia). 50μL
of 20% saline was injected intravenously so as to establish
parallel conductance volume from shift of PV relations, and
this was used for correction of the cardiac mass volume. LV-
PV relations were also captured by transiently compressing
the inferior vena cava.
LV parameters were computed using cardiac PV anal-
ysis software (PVAN3.2, Millar Instruments) as described
previously [41, 42]. Volume calibrations were performed
with Millar volume calibration cuvette which consists of
a 1cm deep cylindrical block with cylindrical holes of
known diameters ranging from 2 to 11mm ﬁlled with fresh
heparinisedwholeratblood.Thelinearvolume-conductance
regression of the absolute volume in each cylinder versus the
raw signal acquired by the conductance catheter was used
for the volume calibration using PVAN 3.2. Cardiac output
was normalized to body weight [cardiac index (CI)]. The
total peripheral resistance index (TPRI) was calculated by
the following equation: TPRI = MBP/CI [43]. Augmentation
index (AI) was calculated by method suggested by Westerhof
et al. [44].
After measurement of cardiac performance, the rats
were sacriﬁced for detailed necropsy and the kidneys were
collected and stored for histopathological examination.
2.5.4.HistopathologicalExamination. Kidneys collectedwere
subjected to gross and microscopic histopathological exam-
ination. Tissues were ﬁxed in 10% neutral buﬀer formalin.
Approximately, 2-3mm thick kidney transverse and longitu-
dinal sections were dehydrated in graded isopropyl alcohol,
c l e a r e di nx y l e n e ,a n di n ﬁ l t r a t e di np a r a ﬃn[ 45]. Three
serial sections of tissue (4μm) embedded in paraﬃnw e r e
taken on the glass slides. Sections were stained with routine
hematoxylin and eosin stain, with Masson’s trichrome stain
for connective tissue, and with periodic acid Schiﬀ stain
(PAS) [45] to study glomerulosclerosis. Kidney pathology
was evaluated under subheading of glomerulosclerotic index
(GSI), tubulopathy, interstitial ﬁbrosis, and media to lumen
ratio in intra renal artery [40, 46, 47]. For GSI, 100 glomeruli
from each animal were scored from one end to another; care
was taken to avoid the duplication of glomeruli.
All the microscopic changes were evaluated in blinded
fashion in grade scale of 0–4 under the light microscopy
(Leica DM2500) [48], where grade 0 deﬁnes no change in
tissue, grade 1-minimal (11–25%); grade 2-mild (26–50%);
grade 3 moderate (51–75%) and grade 4 severe (>75%)
pathological changes in the tissues.
For thickness of basement membrane of parietal layer
of Bowman’s capsule: 25 glomeruli (complete midline expo-
sure) were photographed under 400x (Leica DM2500) from
each kidney, and parietal layer of Bowman’s capsule width
(μm) was measured at 4 random positions in each glomeru-
lus by calibrated LAS software. Cross-section of intrarenal
artery (arcurate and intralobular) at corticomedullary junc-
tion of transverse section of kidney (near-to-middle area)
was photographed using Leica DM2500 microscope with
attached CCD camera DFC295 (∼30–40% rats in each
group). Care was taken to select the near-to-circular cross-
section of artery. Cross-sectional area of arterial lumen
and medial wall thickness was measured by image analysis
software (Image-pro Plus Version 6.0). Ratio of media-to-
lumen area was calculated [47].
2.5.5. Pharmacokinetic Monitoring. Oral pharmacokinetic
(PK) proﬁling of TRC120038 and candesartan was per-
formed in a satellite group of nontelemetry transmitter
implanted male ob-ZSF1 rats (n = 4i ne a c hg r o u p ) ,
being treated similarly to those implanted with telemetry4 International Journal of Hypertension
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Figure 2: (a) Percent change in MBP over 19 hr after dosing at 12 weeks of age in male ob-ZSF1 rats treated with vehicle and diﬀerent doses
of TRC120038 (dose 1:1.26mg/kg; dose 2:11.8mg/kg; dose 3:45.5mg/kg, p.o., bid.) and candesartan (dose 1:0.03mg/kg; dose 2:0.3mg/kg;
dose 3:1.0mg/kg, p.o., od.). n = 6 in each treatment group. P ≤ 0.05 vehicle versus candesartan dose 2 and 3 and vehicle versus TRC120038
dose 3 by RMANOVA. (b) Weekly average MBP proﬁle (mean of 0–19hr) in male ob-ZSF1 rats upon treatment with vehicle, TRC120038,
or candesartan (n = 8, 11, and 10 resp.) for 25 weeks. ∗P ≤ 0.05 versus vehicle; ∗∗P ≤ 0.05 TRC120038 versus candesartan by one way
ANOVA with multiple comparison using Tukey post hoc test. Also, P ≤ 0.05 for vehicle versus TRC120038 treatment and TRC120038 versus
candesartan treatment by RMANOVA.
transmitters. PK proﬁling was performed on day 1 of
treatment and again at end of 4 months (18 weeks) of
treatment. On the day of PK study, the second evening dose
of TRC120038 was not administered to capture the 24-hours
PK proﬁle.
2.6. Statistical Analysis. Results are expressed as mean ±
SEM for MBP. Statistical comparisons between and within
groups were conducted using analysis of variance by
repeated measures (RMANOVA). One-way ANOVA with
multiple comparisons using Tukey as post hoc test was used
for comparisons amongst groups. Graded data of kidney
histopathological analysis was subjected to nonparametric
chi-square test. Values exceeding 95% critical limits (P ≤
0.05) are considered to be statistically signiﬁcant. Statistical
analysis has been performed using statistical analysis system
(SAS, Version-9.1) and GraphPad Prism (version 3.0).
3. Results
3.1. Antihypertensive Activity of TRC120038 and Candesartan
Dose Response. A dose-dependent fall in MBP was observed
with three incremental doses of TRC120038, whereas
maximum fall in MBP with candesartan was observed
with its second dose (0.3mg/kg) itself (Figure 2(a)). Dose
response revealed that AUC(0−19hr) for net MBP change
(691.5 ± 40.9mmHg·hr) seen with dose 2 of TRC120038
(11.8mg/kg) was similar to that observed with maximal
eﬀective dose 2 of candesartan (0.3mg/kg) (662.8 ±
13.1mmHg·hr).
3.2. Repeat Dose Eﬃcacy Study with
TRC120038 and Candesartan
3.2.1. Antihypertensive Activity of TRC120038 and Candesar-
tan. Ob-ZSF1 rats followed up for 25 weeks of treatmentInternational Journal of Hypertension 5
Table 1: Terminal left ventricular functional parameters of male ob-ZSF1 rats treated with vehicle, TRC120038, or candesartan.
Left Ventricular functional Parameters Vehicle 1mL/kg TRC120038
11.8mg/kg, bid, po
Candesartan
0.3mg/kg, od, po
Mean ± SEM (n = 8) Mean ± SEM
(n = 11)
Mean ± SEM
(n = 10)
Heart rate (bpm) 264.1 ±9.1 274.1 ±14.1 266.4 ±17.1
Minimum volume (μL) 80.8 ±14.73 8 .0 ±8.4
∗,∗∗ 82.0 ±11.8
End systolic volume (μL) 97.2 ±14.14 8 .0 ±11.1
∗,∗∗ 91.9 ±10.8
End diastolic volume (μL) 139.7 ±19.5 101.0 ±12.8
∗,∗∗ 144.0 ±13.5
End systolic pressure (mmHg) 180.4 ±10.3 133.0 ±11.9
∗ 149.2 ±11.7
∗
End diastolic pressure (mmHg) 13.7 ±3.17 .5 ±1.0∗ 7.2 ±0.8
∗
Stroke volume (μL) 65.4 ±7.27 3 .0 ±8.77 2 .4 ±4.2
Ejection fraction (%) 46.7 ±4.86 9 .4 ±5.0
∗,∗∗ 48.7 ±3.6
Cardiac output (μL/min) 17143.6 ±1815.0 20298.4 ±2920.0 19018.4 ±1241.0
Arterial elastance (mmHg/μL) 3.0 ±0.42 .1 ±0.3
∗ 2.1 ±0.2
∗
Tau w( m s e c ) 15.9 ±1.01 2 .2 ±0.5
∗ 12.8 ±0.6
∗
Total peripheral resistance index 5.4 ±0.83 .6 ±0.6
∗ 3.9 ±0.4
∗
Augmentation Index 0.4 ±0.04 0.3 ±0.04
∗ 0.4 ±0.05
∗P ≤ 0.05 versus vehicle; ∗∗P ≤ 0.05 versus candesartan by Student’s t-test.
Data represent mean ± SEM (standard error mean).
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Figure 3: Representative pressure-volume loops from left ventricle
of male ob-ZSF1 rats treated with vehicle, TRC120038, or candesar-
tan.
and maintained on 0.5% salt in drinking water displayed
a modest increase in MBP. At 25 weeks of treatment
with vehicle, a rise of 16.4mmHg and 3mmHg in systolic
blood pressure (SBP) and diastolic blood pressure (DBP),
respectively,wasobserved. Therise in MBPwasprevented by
candesartan, whereas TRC120038 was successful in further
lowering the MBP across time in comparison to levels
before initiation of treatment (Figure 2(b)). TRC120038
withinsevendaysoftreatmentproducedsigniﬁcantlygreater
fall in MBP in comparison to vehicle and candesartan
(Figure 2(b)), and this trend continued throughout the
study duration, of 25 weeks. Though both TRC120038 and
candesartan were able to prevent rise and maintain lower
SBP and DBP, the magnitude of fall in SBP and DBP brought
aboutbyTRC120038treatmentwasgreaterincomparisonto
candesartan treatment (23.6 versus 16.1mmHg for SBP and
13.1 versus 7.5mmHg for DBP, resp.).
3.2.2. Eﬀect on Left Ventricular Performance. Representative
LV-PV loops and eﬀect of treatment on LV functional
parameters are shown in Figure 3 and Table 1,r e s p e c t i v e l y .
EvaluationofcardiacfunctionrevealedabilityofTRC120038
to signiﬁcantly prevent rise in indices of preload (end
diastolic pressure (EDP) and end diastolic volume (EDV))
and afterload (end systolic volume (ESV), arterial elastance,
and TPRI); prevent deterioration in diastolic function as
evident from better preserved time constant of LV pressure
decay (tau), lesser EDP; additionally, the minimum pressure
during cardiac cycle in diastole was signiﬁcantly less in com-
parison to vehicle-treated group. Further, the reduced AI in
TRC120038-treatment group indicates ability of TRC120038
to prevent rise in arterial stiﬀness in comparison to vehicle
treated ob-ZSF1 rats. Also, TRC120038 treated group was
found signiﬁcantly better to candesartan treated group in
preventing rise in preload (EDV), cardiac performance
[ejection fraction (EF)] and a trend towards better preserved
afterload [end systolic pressure (ESP)] and AI.
3.2.3. Renal Eﬀect. Percent increases from baseline (before
treatment initiation) for urinary protein and rise in albu-
min to creatinine ratio, over the treatment duration, were
signiﬁcantly prevented in the TRC120038 treated group as
compared to vehicle control as shown in Figures 4(a) and
4(b). Though similar functional improvement in percent
change in urinary protein excretion was observed with
candesartan treatment a better trend was still evident with
TRC120038 treatment reaching signiﬁcance at some points
(Figure 4(a)).
3.2.4. Histopathological Changes in Kidney. Histopathologi-
cal examination of kidney from ob-ZSF1 rats revealed signs
of moderate-degree nephropathy. Focal-to-global sclerosis of6 International Journal of Hypertension
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Figure 4: (a) Percent change from basal levels in urinary protein
excretion proﬁle of male ob-ZSF1 rats treated with vehicle,
TRC120038, or candesartan. ∗P ≤ 0.05 versus vehicle; ∗∗P ≤ 0.05
TRC120038 versus candesartan by one-way ANOVA with multiple
comparison using Tukey post hoc test. (b) Urinary albumin to
creatinine ratio proﬁle of male ob-ZSF1 rats treated with vehicle,
TRC120038, or candesartan. ∗P ≤ 0.05 versus vehicle; ∗∗P ≤ 0.05
TRC120038 versus candesartan by one-way ANOVA with multiple
comparison using Tukey post hoc test.
glomeruli, characterized by expansion of mesangial matrix,
thickened basement membrane, hypercellularity, hypertro-
phied podocytes with/without pseudo cyst formation, foam
cells inﬁltration, and obliteration of Bowman’s space result-
ing in sclerosed or obsolesce glomeruli were observed in
all the rats. Tubulopathy included dilated tubules with
loss of brush border, desquamation of tubular epithelium,
hyperplastic/hypertrophic tubular epithelium or ﬂattened
epithelial lining and hyaline cast in tubular lumen. In more
severe cases, atrophic and degenerating tubules along with
regeneratingtubuleswerealsoobserved.Interstitiumshowed
increase in the interstitial space, ﬁbrous tissue proliferation,
and inﬁltration of mono nuclear cells.
Treatment with TRC120038 signiﬁcantly prevented the
deterioration in GSI as evident from greater percentages
of normal glomeruli and glomeruli with minimal scle-
rotic changes in comparison to glomeruli of vehicle and
candesartan-treated rats (Figures 5 and 6). Similarly, both
the treatment groups (TRC120038: 4.07 ± 0.49μma n d
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0
10
20
30
40
50
60
Vehicle TRC120038
11.8mg/kg bid
Candesartan
0.3mg/kg od
G
l
o
m
e
r
u
l
i
(
%
)
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
Figure 5: Percent incidence of glomeruli in diﬀerent grades of GSI
for ob-ZSF1 rats treated with vehicle, TRC120038, or candesartan.
Incidences are signiﬁcantly diﬀerent (P ≤ 0.01) for TRC120038
versus candesartan and vehicle versus TRC120038 by chi-square
test.
candesartan:4.06 ±0.98μm)signiﬁcantlypreventedincrease
in the width of parietal layer of Bowman’s capsule as
compared to vehicle-treated rats (5.08 ± 1.31μm). Further,
a clear trend indicating less severe grade of tubules with
cast and better maintained normal structure of tubules were
observed in TRC120038- (1.65 ± 0.15 and 2.04 ± 0.18, resp.)
and candesartan- (1.79 ± 0.12 and 2.21 ± 0.16, resp.) treated
rats as compared to the vehicle-treated (2.18 ± 0.26 and
1.91 ± 0.25, resp.) ob-ZSF1 rats (Figure 7). Masson trichome
stained kidney section showed the presence of interstitial
ﬁbrosis in all ob-ZSF1 rats. TRC120038-treated ob-ZSF1 rats
had lesser severity (1.23 ± 0.12) of renal interstitial ﬁbrosis
in comparison to the vehicle-treated rats (1.55 ± 0.17) and
candesartan-treated rats (1.50 ± 0.19).
Though not signiﬁcant, a positive trend towards
TRC120038 treatment-related improvement was observed in
the media-to-lumen ratio of intrarenal artery with respect to
other two treatment groups.
3.2.5. Pharmacokinetic Measurements. AUC0−α was 13189 ±
1859 and 9266 ± 1028hr·ng/mL, with Cmax 2610 ± 275 and
2500 ± 858ng/mL on day 1 and after 4-month repeated
administration, respectively, showing no accumulation of
TRC120038 on repeated dosing. Similarly, exposure to
candesartan, determined on ﬁrst day of treatment and
determined again after multiple dosing for 4 months, was
similar with AUC0−α 386.3 ± 40.9, 335.2 ± 9.4hr·ng/mL and
Cmax 55.3 ± 5 and 56.8 ± 8.4ng/mL, respectively.
4. Discussion
In this study, TRC120038, a novel dual AT1/ETA receptor
blocker, on repeated administration, has clearly prevented
increase in BP, attenuated progression in the severity of renal
dysfunction, and preserved cardiac function in ob-ZSF1, an
animal model of metabolic syndrome.
In present study, the anti-hypertensive and cardiorenal
protective eﬀects of our dual AT1/ETA receptor blockerInternational Journal of Hypertension 7
(a) Control (b) TRC120038
(c) Candesartan
Figure 6: (a) Glomerulus from vehicle-treated ob-ZSF1 rat, showing global glomerulo sclerosis, expansion of mesangial matrix (red arrow),
inﬁltration of foamy macrophage (green arrow), podocyte hypertrophy (yellow arrow), thickening of basement membrane (blue arrow),
and complete obliteration of Bowman’s space. PAS staining, 400x (b) Glomerulus from TRC120038-treated ob-ZSF1 rat. (c) Glomerulus
from candesartan treated ob-ZSF1 rat, showing normal glomerulus portion with Bowman’s space (black arrow), focal glomerulosclerosis,
focal expansion of mesangial matrix with hypercellularity (red arrow), and reduced thickening of basement membrane (blue arrow). PAS
staining, 400x.
TRC120038 and a well-established angiotensin receptor
blocker candesartan used clinically as an anti-hypertensive at
a dose which produces almost similar fall in BP were studied.
Dose response generated upon two days of treatment with
TRC120038 or candesartan revealed that candesartan pro-
duced its maximal anti-hypertensive eﬀect in salt-loaded ob-
ZSF1 rats at a dose of 0.3mg/kg, p.o., od., and TRC120038
produced almost similar fall in BP at a dose of 11.8mg/kg,
p.o., bid. These doses were thus selected for subsequent
comparison of eﬃcacy (BP and cardiorenal damage) upon
chronic administration of TRC120038 and candesartan in
ob-ZSF1 rats. Decision to administer TRC120038 twice a
day was based on its PK proﬁle. The dose-response study
shows greater fall in BP with higher doses of TRC120038 as
compared to candesartan. At the studied doses, saturation
in candesartan’s eﬃcacy is seen. The greater fall in BP is
probably due to the additional contribution from the ETA
receptor blockade component of TRC120038.
Here, TRC120038 upon 25 weeks chronic treatment
clearly proved to be a better anti-hypertensive and in addi-
tion, preserved cardiac function and reduced the severity of
renal dysfunction in ob-ZSF1 rats. This additional BP lower-
ing seen on chronic treatment by TRC120038 in comparison
to candesartan could be related to its ETA-receptor-blocking
component which addresses the activated endothelin system
in salt loaded ob-ZSF1 rats. This is also in line with the
observationsthatdiabeticandobesepatientshavehigherET-
1acti vity[12,14].Thepossibility ofadditional improvement
observed with TRC120038 due to its probable increased
systemicexposurewithtimewasruledoutbytheobservation
where exposure to TRC120038 and candesartan, determined
on ﬁrst day of treatment, was similar to that observed at the
end of 18 weeks of repeated dosing.
Diabetic nephropathy is likely to manifest with comor-
bidities like hypertension, cardiomyopathy, and other micro-
vascular complications, and these patients would be on
multiple drug therapy which is high likely to include an
angiotensin-converting enzyme (ACE) inhibitor/AT1 recep-
tor blocker. Though used as a ﬁrst-line therapy, intervening
RAS at the level of ACE or AT1 receptors in renal patients
is shown not to consistently reduce proteinuria, which is
not only a powerful predictor but also a promoter of renal8 International Journal of Hypertension
(a) Control (b) TRC120038
(c) Candesartan
Figure 7: (a) Kidney from vehicle-treated ob-ZSF1 rat, showing more number of dilated tubules (red arrow), tubules with hyaline cast (blue
arrow), sclerosed glomeruli (white arrow), and interstitial inﬂammation (yellow arrow). PAS staining, 40x (b) Kidney from TRC120038. (c)
Candesartan-treated ob-ZSF1 rat, showing normal tubules and glomeruli (white arrow), reduced number of dilated tubules (red arrow),
and tubules with cast (blue arrow). PAS staining, 40x.
dysfunction; this is true for the dosages recommended for
hypertension control and even for supramaximal dosages
[49].
High levels of endothelin are reported in diabetic
nephropathy [50, 51] and diabetic cardiomyopathies [52–
54] and also showed the beneﬁcial eﬀect of endothelin
receptor blocker in cardio-renal syndrome [55]. Similarly,
as expected theoretically, combination of selective ETA
receptor blocker and ACE inhibitor has produced impressive
beneﬁt, including regression of lesions in model of diabetic
nephropathy [56]. These ﬁndings fully justify the notion
that endothelin receptor blocker holds much promise for the
management of diabetic nephropathy.
Dual inhibition of RAS and endothelin system holds
promise in diabetic nephropathy as pharmacologic blockade
of RAS and endothelin independently has been shown
to ameliorate the abnormality in glomerular permeability
selectivity [57–59]. Studies have shown BP-independent
eﬀect of pharmacological blockade of RAS and endothelin
system in reducing indices of renal injury as compared to the
respective monotherapies [27, 60, 61]. In addition, protein
loading of proximal tubular cells is suggested to provoke
tubular expression of ET-1 and secretion of ET-1 [62, 63].
This hypothesis is in good agreement with the ﬁnding of
studies on the expression of ET-1 and endothelin receptors
in human renal biopsy specimens, which demonstrated
more pronounced expression in individuals with marked
proteinuria [64].
Ob-ZSF1 rats display all characteristics of diabetic
nephropathy, which becomes even more severe as model
progresses in age and ultimately animals are reported to
die of nephropathy by age of around one year [40, 46, 65].
Similar were our observations where severity of diabetic
nephropathy was clearly evident by the extent and rate
of increase of proteinuria and terminal histopathological
examination of kidney.
Atthestartofstudy,overthyperglycemiaandproteinurea
were seen in these animals (12wks of age) though hyper-
tension was mild, which leads to the fact that hypertension
has minimal role in development of nephropathy in this
model.Inourstudy,treatmentwithTRC120038resultedinto
better reduction in urinary-albumin-to-creatinine ratio and
protein excretion in comparison to candesartan-treated ob-
ZSF1 rats. These functional beneﬁts are expected to translate
into histopathological ﬁndings as well, since excretion of
proteins has been suggested to have toxic eﬀect on tubularInternational Journal of Hypertension 9
epithelial cells and may be responsible for the initiation
of interstitial inﬂammation and scarring [66, 67]. This
correlates well in our case as TRC120038 treatment was
found superior to even candesartan in having less severe
GSI and tubulo-interstitial pathology. Thus, in our study,
functional improvement in the ability of kidney to prevent
excessive urinary protein excretion with treatment is well
correlatedwithhistopathologicalﬁndingsofbetterpreserved
microscopic structures of kidney.
Major clinical trials with ACE inhibitors have shown
fewer cardiovascular events and a lower rate of macrovas-
cular complications in high-risk diabetic patients [68], sug-
gesting cardioprotective potential of intervening RAS in such
patient population. Evidence is also accumulating which
supports possible importance of the overactive endothe-
lin system in the pathogenesis of diabetic cardiovascular
complications. In hearts from experimental animals with
chemically induced diabetes, mRNA and protein for ET-1
and endothelin receptors were elevated [68]. The increased
expression of mRNA encoding for ET-1 and endothelin
receptors was associated with myocardial cell death, focal
scarring of the myocardium, and increased expression of
several extracellular matrix proteins. All these insults were
mitigated by an endothelin receptor blocker [69]. Similarly,
in diabetic animals, endothelin receptor blockade limited
the rise in BP [70] and antagonized myocardial contractile
depression [71], macrovascular endothelial dysfunction, and
renal target organ damage [72].
The hallmark of diabetic cardiomyopathy which includes
diastolic and systolic dysfunctions is also related to change
in cardiac preload and afterload. TRC120038 successfully
retarded rise in preload and afterload parameters and also
prevented rise in peripheral resistance and stiﬀness of
conduit arteries which is reﬂected well in parameters as
TPRI and AI, respectively. Though not always signiﬁcant,
TRC120038 proved superior to candesartan in preservation
of the LV parameters studied. However, no diﬀerences were
observedinanyoftheLVparameterscapturedaftertransient
occlusion of inferior vena cava which reﬂects preload-
independent functioning of LV. It is possible that by the
end of treatment duration of 25 weeks signiﬁcant structural
changes in myocardium were yet to set in. This is also
supported by no signiﬁcant diﬀerence observed in the heart
weight and other morphometric analysis which includes
length and width of heart.
A direct correlation between high BP and end organ
damage (heart, kidney, and brain) has been long established
andalsoprovenisthefactthatloweringBPdirectlycorrelates
with lesser damage to end organs [73]. The better cardio-
renal protective eﬀectsseenwithTRC120038havesigniﬁcant
contributions from their superior BP control compared to
candesartan, and an additional contribution from blockade
of tissue ET in addition to tissue RAS cannot be ruled out.
5. Conclusion
In conclusion, TRC120038, a dual AT1/ETA receptor blocker,
has clearly shown its multifaceted potential in controlling
hypertension and attenuating diabetic end organ damage in
a way similar, or even better (in several aspects) than can-
desartan. Evidence, like these, provides strong background
for the exploration for dual RAS and endothelin system
blockade for treatment of poorly controlled hypertension
and diabetic end organ damage. Our study with novel dual
AT1/ETA receptorblockerTRC120038providesexperimental
evidence for the beneﬁts of such an approach. However,
outcome of further detailed safety and toxicity studies would
be required to shape the future exploration of this molecule
in target human population.
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